Advertisement
U.S. markets close in 3 hours 41 minutes

Alaunos Therapeutics, Inc. (TCRT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8535-0.0065 (-0.35%)
As of 12:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.8600
Open1.8500
Bid1.5900 x 100
Ask2.1500 x 100
Day's Range1.8350 - 1.8745
52 Week Range0.6000 - 10.5000
Volume8,766
Avg. Volume236,515
Market Cap29.733M
Beta (5Y Monthly)-0.30
PE Ratio (TTM)N/A
EPS (TTM)-2.2500
Earnings DateMar 28, 2024 - Mar 31, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TCRT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alaunos Therapeutics, Inc.
    Technical Assessment: Neutral in the Intermediate-TermWas that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.
    Rating
    Fair Value
    Economic Moat
    5 hours agoArgus Research
View more
  • GlobeNewswire

    Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

    Best Response to TCR-T Best Response to TCR-T TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar

  • GlobeNewswire

    Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

    TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- A

  • GlobeNewswire

    Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

    HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company’s TCR-T therapy in sol